Article Per Year (5 Year)
p-Index From 2020 - 2025
1.288
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Sains dan Komunitas JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Journal of Pharmaceutical and Health Research Jurnal Farmasi SYIFA Journal of Pharmaceutical (JOP) Journal of Health Research and Technology
Novia Ariani Dewi
Master of Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Nursing Public Health

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 7 Documents
Search

 1 
STANDARDIZATION OF EXTRACT AND CHARACTERIZATION OF EMULGEL FORMULA OF LENGKUAS (Alpinia galanga (L.) Willd) RHIZOME EXTRACT Widyasari Putranti; Novia Ariani Dewi; Lina Widiyastuti
Jurnal Farmasi Sains dan Komunitas (Journal of Pharmaceutical Sciences and Community) Vol 15, No 2 (2018)
Publisher : Sanata Dharma University

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (954.698 KB) | DOI: 10.24071/jpsc.001612

Abstract

The lengkuas rhizome has an antifungal activity. The non-specific parameters for extracts of lengkuas rhizome need to be standardized to obtain the extracts with consistent good quality. The lengkuas rhizome extract emulgel topical preparations are easily mixed with active substances that are hydrophobic or hydrophilic. This study aims to obtain a lengkuas rhizome extract emulgel formula that has good quality and good physical properties. Extraction of lengkuas rhizome was obtained using a maceration method with 96% ethanol solvent. The extract is standardized by non-specific parameters. After that, the extract was formulated in the form of emulgel preparation with 10% concentration. The physical properties of emulgel were evaluated. The results of the study showed that the extract yield is of (14.660.056)%; powder drying shrinkage (8.630.134)%; extract water rate (50)%; powder total ash rate (3.240.017)%; and extract (1.300.035)%; acid-insoluble ash rate powder (2.660.10)%; and extract (0.870.031)%; extract type weight 1.01; and the physical properties of emulgel preparations were homogeneous emulgel, semisolid form, light brown color, distinctive smell of lengkuas rhizome extract, stable at 5oC and 25oC for 24 hours; pH 7; spreadability (2.450.03) g.cm.s-1; stickiness (8.800.72) seconds; o/w emulsion type; and viscosity (1.370.22) Pa.s. This study obtained extracts of lengkuas rhizomes that meet the requirements of non-specific parameter standardization in general and the formulation of lengkuas rhizome extract emulgel had good physical properties.
Narrative Review: Terapi Kortikosteroid Pada Pasien COVID-19 dengan Komorbiditas Diabetes Melitus Novia Ariani Dewi; Tri Murti Andayani; Ika Trisnawati
Journal of Pharmaceutical and Health Research Vol 4 No 2 (2023): June 2023
Publisher : Forum Kerjasama Pendidikan Tinggi (FKPT)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47065/jharma.v4i2.3713

Abstract

COVID-19 is a respiratory disease caused by SARS-CoV-2, a corona virus that was discovered at the end of 2019. Diabetes mellitus (DM) is the second highest comorbidities in Indonesia of COVID-19 patients. One of the treatments for COVID-19 patients is corticosteroids. Commonly used corticosteroids are dexamethasone, methylprednisolone, and hydrocortisone. This study aims to determine the effect of corticosteroid therapy in COVID-19 patients with DM comorbidities so that it can be a source of information and a reference in the management of therapy in patients. This research is a narrative review using literature from the science databases Cochrane, PubMed and Science Direct. Literature search used the keywords COVID-19, diabetes, and corticosteroids. The results of the literature screening obtained 16 study articles that met the inclusion criteria. The conclusion of this narrative review study is that the recommended corticosteroid therapy for COVID-19 patients is dexamethasone. Administering corticosteroids to COVID-19 patients with comorbid DM can increase the incidence of hyperglycemia, especially at high doses and in the long term, thereby worsening the patient's prognosis, causing new onset diabetes, and increasing the need for insulin doses.
Mekanisme Interaksi Obat Pada Pasien Lansia Hipertensi Titami, Arina; Dewi, Novia Ariani
Jurnal Farmasi SYIFA Vol 2 No 2 (2024): Jurnal Farmasi SYIFA
Publisher : CV. Wadah Publikasi Cendekia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.63004/jfs.v2i2.460

Abstract

Populasi lansia berada pada risiko tinggi terkait drug-related problems (DRPs) karena perubahan farmakokinetik dan farmakodinamik terkait usia. Insiden terkait DRPs dapat dihasilkan dari peningkatan prevalensi multipel penyakit kronis terkait usia yang menyebabkan penggunaan rejimen terapi yang kompleks. Interaksi obat adalah DRPs yang paling banyak terjadi pada penggunaan obat antihipertensi pada pasien lansia. Penelitian bertujuan untuk mengetahui potensi interaksi obat beserta mekanismenya yang mungkin terjadi pada pasien lansia dengan hipertensi. Penelitian ini merupakan review artikel, subjek review yang digunakan adalah artikel yang terindeks secara nasional dan internasional pada 10 tahun terakhir (2013-2023). Data yang diperoleh berasal dari situs web penyedia jurnal elektronik yaitu Google Scholar dan Researchgate. Pencarian artikel berdasarkan kata kunci yang digunakan yaitu interaksi obat, hipertensi, lansia. Potensi terjadi interaksi obat bergantung pada golongan obat dan mekanisme kerja obat tersebut. Terdapat 4 golongan obat yang digunakan sebagai lini pertama pada pengobatan hipertensi yaitu diuretik, B-blocker, ACE Inhibitor, dan ARB. Potensi interaksi obat dapat terjadi antara obat antihipertensi (OAH) dengan obat lainnya berupa obat antihipertensi golongan lain, NSAID, kortikosteroid, dan lainnya.Sebagian besar interaksi obat dapat diprediksi, dicegah dan diminimalisasi efek sampingnya dengan pemahaman yang baik tentang mekanisme interaksi obat. Pengetahuan yang baik tentang interaksi obat akan meningkatkan kesiagaan tenaga kesehatan khususnya apoteker dalam menangani kejadian yang tidakdiinginkan pada terapi farmakologi untuk pasien.
Review Artikel: Pengaruh Glukokortioid Terhadap Glukosa Darah Pasien Diabetes Melitus Tipe 2 Dewi, Novia Ariani; Titami, Arina
Jurnal Farmasi SYIFA Vol 2 No 2 (2024): Jurnal Farmasi SYIFA
Publisher : CV. Wadah Publikasi Cendekia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.63004/jfs.v2i2.463

Abstract

Terapi kortikosteroid khususnya glukokortikoid merupakan terapi penting dalam pengobatan dan profilaksis berbagai inflamasi akut dan kronis serta gangguan autoimun. Penggunaan kortikosteroid dengan dosis tinggi dan secara jangka panjang dapat menimbulkan peningkatan glukosa darah pasien bahkan dapat menyebabkan munculnya penyakit diabetes, terutama pada individu yang sebelumnya mengalami resisten insulin atau obesitas. Peningkatan risiko diabetes ini terjadi karena adanya perubahan metabolisme karbohidrat, termasuk resistensi insulin dan penurunan ambilan glukosa perifer terkait dengan penggunaannya. Penelitian ini bertujuan untuk mengetahui pengaruh glukokortikoid terhadap glukosa darah pasien diabetes melitus tipe 2. Penelitian ini merupakan review artikel yang ditulis berdasarkan hasil meninjau beberapa artikel atau literatur terkait. Hasil dari review artikel ini diperoleh delapan artikel untuk selanjutnya dilakukan pembahasan mendalam pada masing-masing jurnal. Penggunaan glukokortikoid semakin luas dibutuhkan pada dunia kesehatan, namun penggunaan glukokortikoid dapat meningkatkan terjadinya hiperglikemia pada pasien. Mekanisme peningkatan glukosa darah akibat penggunaan glukokortikoid yaitu meningkatkan resistensi insulin pada pasien. Pasien dengan atau tanpa diabetes melitus tipe 2 sebelumnya ketika akan mendapatkan terapi kortikosteroid atau glukokortikoid hendaknya dilakukan pemeriksaan terlebih dahulu terkait risiko terjadinya efek samping obat yaitu peningkatan glukosa darah pasien.
Evaluation of Efficiency of Drug Storage in Pharmacy Warehouses Of Primary Health Center (PHC): A review Novia Ariani Dewi; Yuni Andriani; Vera Anggie Almatiin
Journal of health research and technology Vol. 3 No. 1 (2025): Journal of health research and techonology
Publisher : Sahabat Publikasi Kuu

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58439/jhrt.v3i1.267

Abstract

Primary Health Center (PHC) is a place to provide health services for individuals and public health that requires providing preventive, intensive, curative, and rehabilitative services in community health centers under the supervision of the District/City Health Office. Management of pharmaceutical preparations that begins with planning, requesting, receiving, storing, distributing, controlling, recording and reporting as well as monitoring and evaluation. Drug storage functions to supervise and protect against physical or chemical damage so that it is easy to find, quality can be maintained and drug preparations are not lost or damaged. This study is a review of articles written based on the results of reviewing several articles or literature related to the efficiency of drug storage in pharmacy warehouses. There are several indicators that are still not in accordance with several research results. The efficiency of drug storage in several health center pharmacy warehouses still does not meet the established indicator standards. Drug storage efficiency is very important for the following reasons, namely to maintain patient safety, optimize cost management, facilitate drug accessibility, and improve service quality that will have a positive impact on the agency.
Laporan kasus: Tata laksana terapi sirosis hepatik pada pasien geriatri Novia Ariani Dewi; Lutfi Hidiyaningtyas; Shalahuddin Al Madury
JOURNAL OF PHARMACEUTICAL (JOP) Vol. 2 No. 2, Special Edition (2024): Journal of Pharmaceutical (JOP)
Publisher : Lembaga Penelitian dan Pengabdian kepada Masyarakat (LPPM) UNIVERSITAS JENDERAL ACHMAD YANI YOGYAKARTA

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30989/jop.v2i2, Special Edition.1466

Abstract

Background: Cirrhosis Hepatic is a late-stage liver disease that can be caused by various causes, including metabolic disorders or ongoing hepatitis B and hepatitis C virus infections, auto-immune, alcohol consumption, fatty liver or other diseases that cause bile duct obstruction, and genetics. Cirrhosis of the liver is irreversible or cannot be cured which ends with a liver transplant, the treatment is only done to treat complications. Objective: Provides details about the patient's condition, diagnosis, treatment, and results obtained so that it can be used as a reference for providing therapy to geriatric patients diagnosed with hepatic cirrhosis. Method: This study is a case report that occurred in a hospital X in the city of Semarang. Case data were collected through various methods, such as interviews, observations, documentation, and patient visits. All patient-related data were recorded and comprehensively assessed to see the suitability of therapy for patients by comparing it with existing literature. Result: The patient received treatment, namely 25% albumin infusion 100 ml every 24 hours, ampicillin sulbactam injection 1 g/0.5 g every 12 hours, spironolactone tablets 100 mg every 24 hours, N-acetylcysteine ??200 mg every 8 hours, ursodeoxycholic acid capsules 250 mg every 12 hours, slow-release morphine tablets 10 mg every 24 hours. Conclusion: In this case, the treatment given is in accordance with the patient's condition, but there are several things that must be considered regarding the dosage of slow-release morphine tablets. In elderly patients, in addition to patient treatment, patients also need to undergo a comprehensive geriatric assessment to improve the success of therapy and the patient's quality of life.
Clinical Outcomes for Severe COVID-19 Patients with Comorbid Type 2 DM through Dexamethasone Therapy at RSUP Dr. Sardjito Yogyakarta Dewi, Novia Ariani; Andayani, Tri Murti; Trisnawati, Ika
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 15, No 3
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.96954

Abstract

Background: Dexamethasone is a recommended therapy for severe COVID-19 patients who require hospital treatment. However, its use can affect blood glucose levels in patients, especially patients with diabetes mellitus comorbidity.Objectives: This study aims to determine the clinical outcomes for type 2 diabetes mellitus (DM) patients with Severe COVID-19 comorbidity through dexamethasone as COVID-19 therapy.Methods: This study employed the retrospective cohort an analytical observational research approach. Involving 60 patients as subjects, patients over the age of 18 received dexamethasone at RSUP Dr. Sardjito Yogyakarta between June 2021 and March 2022 and whose RT-PCR results showed severe COVID-19 with comorbidity of type 2 DM were included in the study. The blood glucose profiles derived from the patient's medical record data were the clinical outcome that already checked. The paired t-test was performed to analyze how dexamethasone affected the clinical results of the blood glucose profile.Results: The findings of the study were identified after using dexamethasone for four days, which showed that 78.30% of patients had an increased in blood glucose. Pre and post treatment of dexamethasone for four days had a significant impact on the patient’s blood glucose levels in this study, with an average change in blood glucose levels is 78.32 ± 116.77 (p<0.05).Conclusion: Dexamethasone therapy demonstrates a significant effect on blood glucose levels, resulting in a statistically difference between pre and post values for four days in patients with severe COVID-19 with type 2 DM comorbidity. Consequently, special monitoring needs to be carried out in severe COVID-19 patients with type 2 DM who receive dexamethasone to avoid worsening of the patient’s clinical condition.
Co-Authors Farni Yuliana Pratiwi Hadiatussalamah Ika Trisnawati Ika Trisnawati, Ika Intan Adevia Rosnarita Lina Widiyastuti Lutfi Hidiyaningtyas Shalahuddin Al Madury, Shalahuddin Al Titami, Arina Tri Murti Andayani Vera Anggie Almatiin Widyasari Putranti Yuda Anzas Mara Yuni Andriani